When did Allogene Therapeutics report Q4 2024 earnings?

Allogene Therapeutics (ALLO) reported Q4 2024 earnings on March 13, 2025 after market close.

What were Allogene Therapeutics's Q4 2024 revenue and EPS?

Allogene Therapeutics reported revenue of $22.0K and diluted EPS of $-0.28 for Q4 2024.

Did Allogene Therapeutics beat estimates in Q4 2024?

Revenue beat the consensus estimate of $12.0K by $10.0K. EPS beat the consensus estimate of $-0.34 by $0.06.

Where can I find Allogene Therapeutics's Q4 2024 SEC filings?

You can read the 10-K periodic report (0001737287-25-000036) directly on SEC EDGAR. The filing index links above go to sec.gov.

Allogene Therapeutics ALLO Q4 2024 Annual earnings

Reported March 13, 2025 · After market close

Revenue$22.0KBeat by $10.0K Diluted EPS-$0.28Beat by $0.06

Revenue estimate$12.0K

EPS estimate-$0.34

Next report

Aug 12, 2026 (in a month)

Revenue estimate$2.2K

EPS estimate-$0.16

Financials

Q4 2024

Income statement

See full

Revenue--100%

Operating income-$60.5M+28.9%

Net income-$59.9M+30.1%

EPS (diluted)-$0.28+45.1%

Balance sheet

See full

Cash & equivalents$85.5M-8.5%

Total debt$90.8M-4.6%

Total equity$422.2M-17.6%

Total assets$548.7M-14.6%

Cash flow

See full

Operating cash flow-$36.7M+31.7%

CapEx$257.0K+42.0%

Free cash flow-$37.0M+31.4%

Valuation & ratios

Valuation

as of 12/31/24

See full

Market cap$446.6M-17.3%

Enterprise value$451.85M-16.6%

P/S20,300.1×+14,614×

Profitability

See full

Operating margin-1,241,813.6%-2,018,140pp

Net margin-1,170,863.6%-2,007,890pp

FCF margin-913,609.1%-1,474,890pp

Returns & leverage

See full

Return on equity-55.1%-0.4pp

Debt / equity0.2×0.0×

Current ratio8.5×-3.8×

Versus estimates

Revenue

Q4 2024$22.0KBeat by $10.0K

Diluted EPS

Q1 2026-$0.18Beat by $0.01 Q4 2025-$0.17Beat by $0.08 Q3 2025-$0.19Beat by $0.04 Q2 2025-$0.23Beat by $0.05 Q1 2025-$0.28In line

Q4 2024-$0.28Beat by $0.06

Ask the moment Allogene Therapeutics reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI

Claude

Questions, answered.

When did Allogene Therapeutics report Q4 2024 earnings?: Allogene Therapeutics (ALLO) reported Q4 2024 earnings on March 13, 2025 after market close.
What were Allogene Therapeutics's Q4 2024 revenue and EPS?: Allogene Therapeutics reported revenue of $22.0K and diluted EPS of $-0.28 for Q4 2024.
Did Allogene Therapeutics beat estimates in Q4 2024?: Revenue beat the consensus estimate of $12.0K by $10.0K. EPS beat the consensus estimate of $-0.34 by $0.06.
Where can I find Allogene Therapeutics's Q4 2024 SEC filings?: You can read the 10-K periodic report (0001737287-25-000036) directly on SEC EDGAR. The filing index links above go to sec.gov.